US FDA warns API firm Hebei Yuxing Bio-Engineering
Banned API firm Hebei Yuxing Bio-Engineering has had a microbial contamination problem at its plant since 2013 according to the US FDA.
Archives for September 20, 2016
The riskiest drugs to develop? Diabetes treatments, says Tufts report
While the demand for new diabetes therapies grows, the development of endocrine drugs is riskier than all other drug development, according to a study conducted by the Tufts Center for the Study of Drug Development.
update
Almac: investment to ensure space, staff, larger US footprint
Yesterday, Almac Group announced a $5.2m investment in its US-based operations, which its global VP of operations said will support customers “across the drug development lifecycle.”
Moderna to spend $110m on mRNA therapeutics manufacturing plant
Moderna Therapeutics has announced plans for a $110m (€98m) API manufacturing facility for its pipeline of mRNA therapeutics.
Survey: 97% plan to use digital health tech in trials over next five years
Digital health devices are increasingly being used by the industry to collect patient-generated data in clinical trials and improve medication adherence – and adoption is expected to increase.
Cell and gene therapy investment to continue to grow post-Brexit, CGT Catapult
Brexit will not stifle interest in the UK’s cell and gene therapy space, says the CGT Catapult which has reported a tenfold growth in investment since 2012 to £400m ($520m).